A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A00003518" target="_blank" >RIV/00216208:11120/12:00003518 - isvavai.cz</a>

Alternative codes found

RIV/00064211:_____/12:#0000126

Result on the web

<a href="http://dx.doi.org/10.1093/annonc/mdr030" target="_blank" >http://dx.doi.org/10.1093/annonc/mdr030</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/annonc/mdr030" target="_blank" >10.1093/annonc/mdr030</a>

Result language

angličtina

Original language name

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Original language description

This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomized (1 : 1) to receive six or fewer 3-week cycles of i.v. gemcitabine (1250 mg/m(2) on days 1 and 8) and cisplatin alone (75 mg/m(2) on day 1, control arm) or combined with s.c. PF-3512676 0.2 mg/kg on days 8 and 15 of each chemotherapy cycle and weekly thereafter until progression or unacceptable toxicity (experimental arm). No crossover was planned. The primary end point was overall survival (OS). Results: A total of 839 patients were randomized. Baseline demographics were well balanced. Median OS (11.0 versus 10.7 months; P = 0.98) and median progression-free survival (PFS) (both 5.1 months) were similar between groups. Grade >= 3 hematologic adverse events (AEs), injection-site reactions, and influenza-like

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FC - Pneumology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Oncology

ISSN

0923-7534

e-ISSN

—

Volume of the periodical

23

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

72-77

UT code for WoS article

000298385300011

EID of the result in the Scopus database

—